EMN · XBRL financial data
Eastman Chemical financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (EMN's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,207* | 2,310 | 2,363 | 2,464 | 2,245* | 2,290 | 2,287 | 2,202 | 1,973* | 2,177 | 2,513 | 2,385 |
| Cost of goods and services sold | 1,743* | 1,778 | 1,764 | 1,859 | 1,691* | 1,723 | 1,781 | 1,769 | 1,635* | 1,746 | 1,953 | 1,853 |
| Gross profit | 464* | 532 | 599 | 605 | 554* | 567 | 506 | 433 | 338* | 431 | 560 | 532 |
| Research and development | 57* | 59 | 60 | 65 | 66* | 67 | 67 | 63 | 58* | 60 | 65 | 63 |
| Selling, general and administrative | 191* | 191 | 180 | 183 | 182* | 182 | 157 | 160 | 159* | 178 | 185 | 171 |
| Other income (expense) | year only | — | — | — | year only | — | — | — | year only | — | — | — |
| Income tax expense (benefit) | 114* | 49 | 56 | 99 | (34)* | 70 | 29 | 87 | (93)* | 29 | 72 | (4) |
| Net income (loss) | 310* | 165 | 230 | 180 | 330* | 182 | 140 | 47 | 105* | 107 | 183 | 252 |
| Earnings per share, basic USD per share | 2.62* | 1.40 | 1.96 | 1.55 | 2.85* | 1.58 | 1.22 | 0.41 | 0.92* | 0.93 | 1.60 | 2.21 |
| Earnings per share, diluted USD per share | 2.60* | 1.39 | 1.94 | 1.53 | 2.82* | 1.57 | 1.20 | 0.40 | 0.92* | 0.93 | 1.59 | 2.19 |
| Weighted average shares, basic millions of shares | 118* | 117 | 117 | 116 | 116* | 115 | 115 | 114 | 114* | 114 | 114 | 114 |
| Weighted average shares, diluted millions of shares | 119* | 118 | 119 | 118 | 117* | 117 | 116 | 115 | 114* | 115 | 115 | 115 |
Balance sheet
CSVFiscal quarters (EMN's year ends in late December)
Cash flows
CSVFiscal quarters (EMN's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | 310* | 165 | 230 | 180 | 330* | 182 | 140 | 47 | 105* | 107 | 183 | 252 |
| Depreciation and amortization | year only | 127 | 126 | 127 | 129* | 126 | 127 | 129 | 131* | 131 | 132 | 134 |
| Net cash from operating activities | 452* | (16) | 367* | 396* | 540* | (167) | 233* | 402* | 502* | (137) | 224* | 290* |
| Purchases of property and equipment | 179* | 185 | 115* | 120* | 179* | 147 | 150* | 137* | 112* | 103 | 100* | 95* |
| Net cash from investing activities | 248* | (179) | (121)* | (102)* | (132)* | (131) | (147)* | (137)* | (47)* | (104) | (99)* | (96)* |
| Dividends paid | 94* | 95 | 95* | 95* | 94* | 96 | 95* | 96* | 94* | 96 | 96* | 96* |
| Proceeds from long-term debt | 0* | 742 | 0* | 495* | 0* | 246 | 0* | 0* | 0* | 594 | 0* | 0* |
| Repayments of long-term debt | 0* | 498 | 43* | 498* | 0* | 550 | 0* | 0* | 0* | 150 | 0* | 0* |
| Net cash from financing activities | (593)* | 148 | (227)* | (194)* | (181)* | (124) | (90)* | (201)* | (382)* | 341 | (100)* | (117)* |
| Net change in cash | 109* | (49) | 15* | 108* | 215* | (419) | 5* | 66* | 77* | 99 | 26* | 77* |
Compare with peers
SIC 2821 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2821 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Eastman Chemical | 768 | 2,385 | 290* | 114.4M | 10-QSep 30, 2026 |
| Albemarle | 1,632 | 1,743 | 710* | 118.0M | 10-QJun 30, 2026 |
| Celanese | 1,362 | 2,556 | 538* | 109.8M | 10-QSep 30, 2026 |
| DuPont de Nemours | 1,652 | 1,868 | 410* | 132.5M | 10-QSep 30, 2026 |
| Sealed Air | 344 | 1,401* | 294* | 147.4M | 10-KDec 31, 2025 |
| Hexcel | 78 | 496 | 74* | 75.7M | 10-QSep 30, 2026 |
| Dow | 4,142 | 11,267 | not reported | 723.9M | 10-QSep 30, 2026 |
| EIDP | 2,365 | 6,379 | not reported | 667.2M | 10-QJun 30, 2026 |
| Avient | 426 | 917 | 94* | 91.7M | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.